Ulrich Martin

1 week ago | pipelinereview.com | Ulrich Martin

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to MabThera/Rituxan plus chemotherapy1,2 DLBCL is an aggressive cancer with a high risk of progression meaning urgent and effective treatments are needed for people who relapse or have refractory disease This Columvi regimen offers a much needed off-the-shelf and fixed-duration treatment option for those ineligible for transplant BASEL, Switzerland I...

2 weeks ago | pipelinereview.com | Ulrich Martin

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy THOUSAND OAKS, CA, USA I April 11, 2025 I Amgen (NASDAQ:AMGN) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or after a single line of platinum-based chemotherapy met its primary endpoint at a planned...

2 weeks ago | pipelinereview.com | Ulrich Martin

Based on the Phase 3 CheckMate-9DW trial, Opdivo plus Yervoy demonstrated a statistically significant overall survival benefit compared to investigator’s choice of lenvatinib or sorafenib1In the trial, 38% of patients were still alive at 3 years with this dual immunotherapy vs.

2 weeks ago | pipelinereview.com | Ulrich Martin

ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 SPRING HOUSE, PA, USA I April 10, 2025 I Johnson & Johnson (NYSE: JNJ) today announced new icotrokinra (JNJ-2113) data from a subgroup analysis of...

2 weeks ago | pipelinereview.com | Ulrich Martin

Clinical trial will assess safety, tolerability, pharmacokinetics and pharmacodynamic effects of S-4321 Company plans to develop S-4321 for treatment of a range of autoimmune diseases, such as rheumatoid arthritis, inflammatory bowel disease, and lupus WATERTOWN, MA, USA I April 10, 2025 I Seismic Therapeutic, Inc., the machine learning immunology company, today announced the dosing of the first healthy subject cohort in a Phase 1 clinical trial of S-4321, a novel bifunctional antibody for...